Online program aims to make GLP-1 medications more affordable

A telehealth platform is expanding access to GLP-1 medications used for weight loss and metabolic health, offering a structured program that aims to lower costs and speed up prescribing. Costs for semaglutide-based therapies vary by location, insurance coverage and dosage and can run to roughly $1,200 a month. The online model emphasizes a streamlined intake and prescription process that many patients find burdensome when pursued through traditional routes.

Getting started is simple. New users complete a brief online health intake, with follow-up bloodwork and video consultations as needed. In many cases, MyStart can approve a prescription within 24 hours, and medications can arrive by delivery within 48 hours. The program starts at $299 per month and covers more than injections. Patients receive access to U.S.-board-certified clinicians nationwide, expedited FedEx shipping, personalized dosage adjustments and ongoing support from a dedicated patient care coordination team. MyStart says its approach is designed to pass efficiencies back to patients as it scales, with a longer-term focus on health rather than short-term results.

Affordability at MyStart is also anchored in price transparency. The initial price for medication and ongoing care will not rise from a patient’s original plan, even if their dosage changes over time. The program is overseen by Chief Medical Officer Dr. Ritu Chopra, who emphasizes that MyStart is designed to support patients throughout the GLP-1 care journey, not merely at the point of prescription. The company describes a complete protocol, with under-24-hour turnaround on consultations and 48-hour delivery as part of a structured 90-day program that includes medical oversight. Users can connect with MyStart clinicians as often as needed to discuss side effects, track progress or adjust dosage.

On average, users report meaningful weight loss, with about 22 pounds shed within the first six months of participation. Reviewers have credited the program with renewed confidence and an improved sense of well-being. Beyond weight management, MyStart has expanded into women’s hormone health, metabolic longevity and personalized wellness, aiming to provide a full spectrum of care and broaden access to GLP-1 therapies. The company positions itself as redefining how modern health care can work in a space where high costs and cumbersome processes have traditionally blocked access to effective treatments.

The trend toward telehealth-enabled GLP-1 care comes as patients seek faster, clearer pathways to treatment. Supporters say programs like MyStart reduce wait times, increase price clarity and provide ongoing clinician oversight that helps patients manage side effects and stay on track with their health goals. Critics, meanwhile, caution that such programs must maintain rigorous medical standards and ensure appropriate screening and follow-up beyond initial prescriptions. As the market for GLP-1 medications continues to grow, MyStart says its model offers a template for balancing access, affordability and safety in a field where costs and logistics have often hindered patient progress.